[CHANGING IMMUNE STATUS IN PATIENTS WITH REACTIVE SPONDYLOARTHRITIS OF CHLAMIDIAL GENESIS]

Area of Science:

• Immunology
• Rheumatology
• Infectious Diseases

Background:

• Reactive spondyloarthritis (SpA) is often linked to Chlamydia infections.
• Immune system dysregulation plays a key role in the pathogenesis of reactive SpA.
• Understanding immune deviations is crucial for effective treatment strategies.

Purpose of the Study:

• To identify specific immune parameter deviations in patients with reactive chlamydial spondyloarthritis.
• To evaluate the impact of antichlamydial treatment on immune status.
• To enhance treatment quality through targeted immune correction.

Main Methods:

• Comparative immunological examination of 14 patients with reactive chlamydial SpA before and after treatment.
• Assessment of immune parameters including cytokines (IL-1, IL-4, IL-6, TNF-α), immune cells (CD3, CD4, CD8, CD25), antibodies (CIC, lymphocytotoxic, granulocytotoxic), and autoantigens.
• Microbiological confirmation of pathogen eradication.

Main Results:

• Patients exhibited a perverse immune response with T-lymphocyte hyperactivation, impaired suppression, autoimmune tendencies, and chronic inflammation.
• Antichlamydial treatment led to partial immune normalization, including the neutrophilic/lymphocytic ratio and cytotoxic antibodies.
• Desensitization to cartilage and synovial autoantigens was observed post-treatment.

Conclusions:

• Immune status analysis in reactive chlamydial SpA reveals significant deviations requiring targeted intervention.
• Antichlamydial therapy can partially restore immune balance and reduce autoimmune responses.
• Monitoring immunological parameters is vital for assessing and improving treatment efficacy in reactive chlamydial spondyloarthritis.